NHEK + NHEM, melanocyte dendricity (IBMX stimulation)
KM-0016- Context
- Descriptions
- Requirement
- Study and reporting
- See also
Human skin pigmentation is caused by the synthesis of melanin and by its distribution in skin and in hair follicles. The melanogenesis process is initiated within melanocytes, and more particularly in melanosomes, which are lysosome-related membrane-bound organelles. Melanogenesis starts by the production of non-pigmented pre-melanosomes, which are mostly composed of fibers (Pmel 17 protein). Enzymes (tyrosinase, Tyrp1, DCT) are then transferred to melanosomes for the biotransformation of tyrosine into melanin. Mature melanin-containing melanosomes are transported via a microtubule network to the melanocyte dendritic extremities. In order to transfer the melanosomes to the keratinocyte cytoplasm, melanocytes project their dendrites into the neighboring keratinocytes, at an approximate ratio of one melanocyte to thirty five keratinocytes (one pigmentary unit). Melanosome transfer is a key step of the skin pigmentation process. The purpose of this assay is, by immunofluorescence, to evaluate the capacity of compounds (molecules, active ingredients, extracts, etc.) to inhibit the dendrite formation in a co-culture model of normal human melanocytes and keratinocytes.
| Biological Model | Keratinocytes + Melanocytes, coculture |
|---|---|
| Species | Human |
| EndPoint | TRP-1 immunolabeling |
| Method | Immunofluorescence |
| Stimulation Factor | IBMX (200 µM) |
| Compound Reference | Vincristin |
| Physiopathology | Skin and cutaneous appendices > Melanocyte, pigmentation > Dendricity and melanosome transfer |
Feasibility, study proposal:
Our sales team is here to help you find solutions:
Price: our pricing system consists of a fixed price per study + pricing per unit (price per replicate or experimental condition)
Start of assays and turnaround time: the start of an assay is subject to the receipt of your agreement and of the compounds to be tested. The sending date of the study report is communicated by email when the study starts. Although of an average of 5 to 10 weeks, our turnaround time may be subject to some fluctuation (due to availability of biological samples, to workload, etc.).
Required quantity of compounds: the required quantity is generally of a few mg or ml but may vary according to the form and solubility of compounds and to the concentrations to be tested. Please contact us for an estimation.
Customized protocols: for this assay, as for all of our assays, we can develop a protocol adapted to your needs. Should you have any question, please contact us.
Our sales team is here to help you find solutions:
- Technical feasibility study of your project
- Development of an assay selection strategy
- Definition of an experimental scheme
- Financial assessment and contractual agreements (costs, turnaround time, non-disclosure agreements, etc.)
Price: our pricing system consists of a fixed price per study + pricing per unit (price per replicate or experimental condition)
Start of assays and turnaround time: the start of an assay is subject to the receipt of your agreement and of the compounds to be tested. The sending date of the study report is communicated by email when the study starts. Although of an average of 5 to 10 weeks, our turnaround time may be subject to some fluctuation (due to availability of biological samples, to workload, etc.).
Required quantity of compounds: the required quantity is generally of a few mg or ml but may vary according to the form and solubility of compounds and to the concentrations to be tested. Please contact us for an estimation.
Customized protocols: for this assay, as for all of our assays, we can develop a protocol adapted to your needs. Should you have any question, please contact us.
Study management: each project requires advice and expertise so each study is managed and monitored by a dedicated study director who will be attentive to all your needs and questions.
Validation: the assays listed in the catalogue have undergone a preliminary validation and are subject to Standard Operating Procedures (SOPs) and to validation criteria. However, the robustness of each assay may be different according to the models and to the analytical methods. Please do not hesitate to contact us for more information.
Report and experimental data: our services include the writing of a study report in English or in French. This scientific report is provided in a PDF or Microsoft® Office format.
Laboratory / Location: this assay (as all of our assays) will be carried out in our Gençay laboratory in France.
Validation: the assays listed in the catalogue have undergone a preliminary validation and are subject to Standard Operating Procedures (SOPs) and to validation criteria. However, the robustness of each assay may be different according to the models and to the analytical methods. Please do not hesitate to contact us for more information.
Report and experimental data: our services include the writing of a study report in English or in French. This scientific report is provided in a PDF or Microsoft® Office format.
Laboratory / Location: this assay (as all of our assays) will be carried out in our Gençay laboratory in France.
| Reference | Title | EndPoint | Method |
|---|---|---|---|
| Reference | Title | EndPoint | Method |
| NHEM-0025 | NHEM, cytokines/chemokine release (TNF- alpha stimulation) | *** (must be login) | *** (must be login) |
| NHEM-0024 | NHEM, cytokine/chemokine release (IL-1 alpha stimulation) | *** (must be login) | *** (must be login) |
| KM-0013 | NHEK + NHEM, melanosome transfer (basal) | *** (must be login) | *** (must be login) |
| KM-0020 | NHEK + NHEM, inhibition of melanosome transfer (stimulation mix) | Pmel17 (melanosomes) in CD49f-positive keratinocytes, co-labeling | Flow cytometry |
| SKIN-0017 | Skin maintained ex vivo, Pmel17 expression (basal) | *** (must be login) | *** (must be login) |
| RHEM-0009 | RHEm, Pmel17 expression (basal) | *** (must be login) | *** (must be login) |
| NHEM-0013 | NHEM, melanocyte dendricity (basal) | *** (must be login) | *** (must be login) |
| KM-0011 | NHEK + NHEM, melanocyte dendricity (basal) | *** (must be login) | *** (must be login) |
| NHEK-0089 | NHEK, phagocytic activity (basal) | *** (must be login) | *** (must be login) |
